within Pharmacolibrary.Drugs.ATC.B;

model B02BX08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.00011500000000000002,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.18,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010166666666666666,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.768,
    k12             = 17.9,
    k21             = 17.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B02BX08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Avatrombopag is an orally administered small molecule thrombopoietin receptor agonist that is used to treat thrombocytopenia, particularly in patients with chronic liver disease scheduled to undergo a medical or dental procedure and in patients with chronic immune thrombocytopenia (ITP). It is an approved medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Kuter, DJ, &amp; Allen, LF (2018). Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. <i>British journal of haematology</i> 183(3) 466–478. DOI:<a href=&quot;https://doi.org/10.1111/bjh.15574&quot;>10.1111/bjh.15574</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30203841/&quot;>https://pubmed.ncbi.nlm.nih.gov/30203841</a></p></li><li><p>Virk, ZM, et al., &amp; Al-Samkari, H (2021). An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert opinion on pharmacotherapy</i> 22(3) 273–280. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2020.1841748&quot;>10.1080/14656566.2020.1841748</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33095074/&quot;>https://pubmed.ncbi.nlm.nih.gov/33095074</a></p></li><li><p>Xu, H, &amp; Cai, R (2019). Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. <i>Expert review of clinical pharmacology</i> 12(9) 859–865. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2019.1649137&quot;>10.1080/17512433.2019.1649137</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31352834/&quot;>https://pubmed.ncbi.nlm.nih.gov/31352834</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B02BX08;
